Mrs Jennifer Down
Clinical Medicine, School of Medicine and Population Health
Research Associate
j.m.down@sheffield.ac.uk
+44 114 215 9209
+44 114 215 9209
EU25, E Floor, The Medical School
Full contact details
Mrs Jennifer Down
Clinical Medicine, School of Medicine and Population Health
EU25, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Clinical Medicine, School of Medicine and Population Health
EU25, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9(3). View this article in WRRO
- The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene. View this article in WRRO
- TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. Journal of Bone and Mineral Research, 34(12), 2311-2326. View this article in WRRO
- Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
- Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research. View this article in WRRO
- Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget, 8, 68047-68058. View this article in WRRO
- Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer. Cancer Discovery, 5(1), 35-42.
- High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer. Cancer Research, 70(12), 5163-5173.
- Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. The Prostate, 70(8), 875-882.
- Zoledronic acid prevents the development of myeloma bone disease and increases survival. JOURNAL OF BONE AND MINERAL RESEARCH, 17(7), 1328-1328.
- Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma. BONE, 30(3), 39S-39S.
- Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. BONE, 28(5), S81-S81.
- The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. British Journal of Haematology, 111(1), 283-286.
- Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival. Journal of Bone and Mineral Research, 18(3), 482-492.
All publications
Journal articles
- Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO.. Journal of Clinical Oncology, 42(16_suppl), TPS4621-TPS4621.
- Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. The Journal of Pathology: Clinical Research, 10(2). View this article in WRRO
- Novel methods of targeting IL-1 signalling for the treatment of breast cancer bone metastasis. Cancers, 14(19).
- The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties. Journal of Bone Oncology, 31. View this article in WRRO
- Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9(3). View this article in WRRO
- The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene. View this article in WRRO
- TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. Journal of Bone and Mineral Research, 34(12), 2311-2326. View this article in WRRO
- Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
- Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research. View this article in WRRO
- ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.. PLoS One, 13(6). View this article in WRRO
- CORRIGENDUM FOR “Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development”. Endocrinology, 159(4), 1762-1762.
- Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget, 8, 68047-68058. View this article in WRRO
- Low-dose methotrexate in myeloproliferative neoplasm models.. Haematologica, 102, e336-e339. View this article in WRRO
- Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature Communications, 6(1), ---. View this article in WRRO
- Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development. Endocrinology, 156(9), 3098-3113.
- Prostate cancer cells home to bone using a novelin vivomodel: Modulation by the integrin antagonist GLPG0187. International Journal of Cancer, 136(7), 1731-1740.
- Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer. Cancer Discovery, 5(1), 35-42.
- Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer. Scientific Reports, 3(1). View this article in WRRO
- View this article in WRRO iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer.. PLoS ONE.
- High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer. Cancer Research, 70(12), 5163-5173.
- Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. The Prostate, 70(8), 875-882.
- Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. The Prostate, n/a-n/a.
- Expression of beta-dystroglycan is reduced or absent in many human carcinomas.. Histopathology, 53(5), 561-566.
- The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers. International Journal of Cancer, 121(9), 1958-1966.
- Expression of receptor activator of nuclear factor ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. Journal of Clinical Pathology, 59(7), 716-720.
- Osteoprotegerin (OPG)-a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis?. International Journal of Cancer, 118(8), 1901-1908.
- Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?. Breast Cancer Research and Treatment, 92(3), 207-215.
- Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin. Immunity, 19(6), 849-861.
- Zoledronic acid prevents the development of myeloma bone disease and increases survival. JOURNAL OF BONE AND MINERAL RESEARCH, 17(7), 1328-1328.
- Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma. BONE, 30(3), 39S-39S.
- Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?. BONE, 30(3), 32S-32S.
- Interleukin 2 deficiency induces bone destruction associated with dysregulation of the rank/rank ligand/osteoprotegerin system. Blood, 98(11 PART I).
- Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma. Blood, 98(11 PART I).
- Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. BONE, 28(5), S81-S81.
- Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 98(13), 3534-3540.
- The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. British Journal of Haematology, 111(1), 283-286.
- Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.. BLOOD, 96(11), 360A-360A.
- Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.. BLOOD, 96(11), 761A-761A.
- Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.. JOURNAL OF BONE AND MINERAL RESEARCH, 15(6), 1217-1217.
- Targeting the Tumour Antigen 5T4 using CAR-T Cells for the Treatment of Acute Myeloid Leukaemia. Molecular Cancer Therapeutics.
- Correction: iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer. PLoS ONE, 7(5).
- A case of chondromatosis indicates a synovial stem cell aetiology. Rheumatology, 45(12), 1529-1533.
- Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL-Induced Apoptosis. Journal of Bone and Mineral Research, 19(10), 1712-1721.
- Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival. Journal of Bone and Mineral Research, 18(3), 482-492.
Conference proceedings papers
- Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
- Pathology Against the Clock: Verification of Gene Expression Subtyping for the GUSTO Clinical Trial. JOURNAL OF PATHOLOGY, Vol. 261(SUPPL1) (pp S49-S49)
- Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
- Targeting free light chain (FLC) secretion and the unfolded protein response in myeloma cells using VaN, a combination of repurposed drugs. Experimental Hematology, Vol. 64(Suppl) (pp S74-S75). Los Angeles, USA, 23 August 2018 - 26 August 2018. View this article in WRRO
- TARGETING FREE LIGHT CHAIN (FLC) SECRETION AND THE UNFOLDED PROTEIN RESPONSE IN MYELOMA CELLS USING VAN, A COMBINATION OF REPURPOSED DRUGS. EXPERIMENTAL HEMATOLOGY, Vol. 64 (pp S75-S75)
- Spontaneous fusion between prostate cancer cells: A driver for development of tumor heterogeneity and growth in bone. Bone, Vol. 48(1) (pp S46-S47)
- Bone marrow stromal cell-derived insulin-like growth factor (IGF) II enhances growth and survival of prostate cancer cells and potentiates androgen action. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A94-A94)
- There is a general loss of expression of receptor activator of nFkB ligand (RANKL) in human breast cancers but retention of expression has a significant negative association with expression of oestrogen receptor (ER). JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
- Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is expressed in human breast cancers and has a significant negative association with tumours with poor prognosis.. JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
- Loss of intercellular expression of beta-dystroglycan is a common event in breast cancer. JOURNAL OF PATHOLOGY, Vol. 205 (pp 8-8)
- Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation. JOURNAL OF PATHOLOGY, Vol. 205 (pp 15-15)
- beta-dystroglycan is constitutively expressed at the intercellular junctions of epithelial cells and this expression is frequently absent in common cancers. JOURNAL OF PATHOLOGY, Vol. 205 (pp 6-6)
- Human bone marrow stromal cell derived IGF signaling enhances PSA production as well as proliferation/survival of androgen sensitive prostate cancer cells in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36)
- T-cell-mediated colitis and bone destruction in a murine model of autoimmunity are both driven by RANK/RANK LIGAND interactions and modulated by recombinant Fc-OPG. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 125 (pp 67-67)
- Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29)
- T cell mediated colitis and bone destruction are driven by RANK/RANK LIGAND interactions and can be modulated by recombinant Fc-OPG.. BLOOD, Vol. 102(11) (pp 528A-528A)
- Source of maternal serum osteoprotegerin during human pregnancy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1376-1376)
- The role of osteoprotegerin in breast and prostate cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17(7) (pp 1339-1339)
- OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S)
Preprints
- A repurposed drug combination (VaN) inhibits free light chain secretion and triggers the terminal unfolded protein response (UPR) in multiple myeloma (MM), Research Square Platform LLC.
- The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties, Cold Spring Harbor Laboratory.